Q-omics provides the consensus-scored MUC19 profile across patient tissues and cancer cell-line models. MUC19 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MUC19 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MUC19 RNA expression shows 9,780 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where MUC19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC19 survival associations across molecular data types. MUC19 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC19 RNA expression–survival associations across cancer types. High MUC19 expression shows unfavorable associations in BLCA, KIRC, MESO, READ, ACC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify BLCA as the clearest survival context for MUC19 RNA expression.
This table summarizes MUC19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MUC19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC19 shows lower tumor expression in KIRC and higher tumor expression in BRCA, COAD, CHOL, LIHC and BLCA. The KIRC box plot shows higher MUC19 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p < 0.001).
This table shows molecular features associated with MUC19 in patient tissues and cancer cell lines. In patient samples, MUC19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
